Exelixis
EXEL
£28.55
Share price
0.60%
Change (1 day)
52.39%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Total debt
Total debt on the balance sheet as of December 2024 : £0.14 Billion
According to Exelixis's latest financial reports the company's total debt is £0.14 Billion. A company’s total debt is the sum of all current and non-current debts.
Exelixis - Total debt on balance sheet (from 2000 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | £0.15 B | 1.99% |
| 2023-12-31 | £0.14 B | -5.15% |
| 2022-12-31 | £0.15 B | 313.84% |
| 2021-12-31 | £37.98 M | 5.48% |
| 2020-12-31 | £36.01 M | -1.64% |
| 2019-12-31 | £36.61 M | 211.58% |
| 2018-12-31 | £11.75 M | 6.31% |
| 2017-12-31 | £11.05 M | -92.79% |
| 2016-12-31 | £0.15 B | -45.65% |
| 2015-12-31 | £0.28 B | 23% |
| 2014-12-31 | £0.22 B | 8.92% |
| 2013-12-31 | £0.21 B | 1.34% |
| 2012-12-31 | £0.20 B | 77.87% |
| 2011-12-31 | £0.11 B | -13.52% |
| 2010-12-31 | £0.13 B | 174.46% |
| 2009-12-31 | £49.2 M | -38.72% |
| 2008-12-31 | £80.29 M | 31.27% |
| 2007-12-31 | £61.16 M | -1.52% |
| 2006-12-31 | £62.1 M | -28.05% |
| 2005-12-31 | £86.31 M | 12.46% |
| 2004-12-31 | £76.75 M | 23.6% |
| 2003-12-31 | £62.09 M | 34.68% |
| 2002-12-31 | £46.11 M | 36.6% |
| 2001-12-31 | £33.75 M | 237% |
| 2000-12-31 | £10.01 M | 21.69% |
| 1999-12-31 | £8.23 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 | £16.48 B | 11,070.51% | 🇬🇧 UK |
 | £14.41 B | 9,664.70% | 🇫🇷 France |
 | £28.70 B | 19,347.87% | 🇺🇸 USA |
 | £39.59 B | 26,731.15% | 🇺🇸 USA |
 | £46.48 B | 31,394.63% | 🇺🇸 USA |
 | £28.33 B | 19,097.90% | 🇺🇸 USA |
 | £49.22 B | 33,254.99% | 🇺🇸 USA |
 | £2.52 M | -98.29% | 🇺🇸 USA |
 | £29.91 M | -79.73% | 🇺🇸 USA |